Content » Vol 94, Issue 5

Investigative Report

High Incidence of Naevi-associated BRAF Wild-type Melanoma and Dysplastic Naevi under Treatment with the Class I BRAF Inhibitor Vemurafenib

Supplementary content
Figure S1
Licenses
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.